Loading…
VivoSim Labs, Inc. is projected to decline to $1.27 by 2027, a -1% move from its current price of $1.29. VIVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.26 | $1.29 | $1.33 | +0.02% |
| May 30 | $1.24 | $1.29 | $1.34 | +0.04% |
| May 31 | $1.23 | $1.29 | $1.35 | +0.05% |
| Jun 1 | $1.22 | $1.29 | $1.36 | +0.07% |
| Jun 2 | $1.22 | $1.29 | $1.37 | +0.09% |
| Jun 3 | $1.21 | $1.29 | $1.38 | +0.11% |
| Jun 4 | $1.20 | $1.29 | $1.39 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.20 | $1.29 | $1.39 | +0.12% |
| Week 2 | $1.17 | $1.29 | $1.43 | +0.25% |
| Week 3 | $1.15 | $1.29 | $1.46 | +0.37% |
| Week 4 | $1.13 | $1.30 | $1.49 | +0.50% |
| Week 5 | $1.11 | $1.30 | $1.52 | +0.62% |
| Week 6 | $1.09 | $1.30 | $1.54 | +0.75% |
| Week 7 | $1.08 | $1.30 | $1.57 | +0.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models, and bespoke services in investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
The company also provides liver toxicology predictive screening and research services, and works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
In addition, it offers a 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc.
in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
VivoSim Labs, Inc. trades in the Healthcare sector under the symbol VIVS. The stock is currently priced at $1.36 and sits in a small-cap range with a market capitalization of $3.94M and a rank of 5395.
Forecast data indicate a gradual upside over time, with 2026 averaging $1.36, and longer horizons showing rising averages and bullish sentiment in later years. By 2030 the average is expected to be $1.67 with a 22.9 ROI, by 2040 an average of $2.29 with a 68.3 ROI, and by 2050 an average of $3.99 with a 193.5 ROI; the forecast also shows a bullish stance for 2029, 2032, 2034, 2035, 2040 and 2050.
A major floor 18.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
The nearest ceiling, 24.8% above — a clean break opens room to run.
A major ceiling 126.4% above — clearing it would confirm fresh momentum.
Key VIVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VIVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.32 | Sell | $1.31 | Sell |
| MA 10 | $1.30 | Sell | $1.32 | Sell |
| MA 20 | $1.35 | Sell | $1.36 | Sell |
| MA 50 | $1.49 | Sell | $1.50 | Sell |
| MA 100 | $1.76 | Sell | $1.71 | Sell |
| MA 200 | $2.13 | Sell | $2.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.26 | Neutral |
| Stoch RSI (14) | 50.67 | Neutral |
| CCI (20) | -78.90 | Neutral |
| Williams %R (14) | -85.71 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -7.19 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 14.29 | Buy |
| TRIX (15) | -0.65 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 43.11 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 1.33 | Sell |
| ADX (14) | 24.20 | Sell |
| ATR (14) | 0.03 | Info |
The near-term technical picture shows neutral momentum with an RSI14 of 40. The price is trading below the SMA50 of $1.51 and the SMA200 of $2.14, signaling softness relative to the longer-term trend. Support sits at $1.27 and resistance at $1.61, framing a near-term range around current levels.
The thirty-day trading range spans from $1.14 to $1.62, illustrating limited upside momentum in the immediate term. Annualized volatility stands at 50%, underscoring a high level of price fluctuation over time.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.27 | $1.29 | $1.57 | 0% | Neutral | |
| $1.01 | $1.27 | $1.70 | -1% | Neutral | |
| $1.03 | $1.34 | $1.84 | +4% | Neutral | |
| $1.21 | $1.60 | $2.26 | +24% | Bullish | |
| $1.18 | $1.59 | $2.31 | +23% | Bullish | |
| $1.08 | $1.47 | $2.18 | +14% | Neutral | |
| $1.12 | $1.56 | $2.36 | +21% | Bullish | |
| $1.08 | $1.53 | $2.34 | +18% | Neutral | |
| $1.12 | $1.61 | $2.51 | +25% | Bullish | |
| $1.32 | $1.92 | $3.04 | +49% | Bullish | |
| $1.40 | $2.17 | $3.64 | +68% | Bullish | |
| $2.17 | $3.78 | $6.93 | +193% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.27 | $1.29 | $1.52 | +0.00% |
| June 2026 | $1.14 | $1.33 | $1.60 | +3.36% |
| July 2026 | $1.11 | $1.31 | $1.60 | -1.67% |
| August 2026 | $1.10 | $1.31 | $1.61 | -0.28% |
| September 2026 | $1.12 | $1.34 | $1.66 | +2.52% |
| October 2026 | $1.09 | $1.32 | $1.64 | -1.75% |
| November 2026 | $1.04 | $1.25 | $1.57 | -4.90% |
| December 2026 | $1.02 | $1.24 | $1.57 | -0.98% |
Click any year to see its month-by-month VIVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VIVS price prediction for 2026 points to an average of $1.29 (low $1.27, high $1.57) — a potential gain of 0% on today's $1.29. A consolidation phase looks the most probable path here.
In 2027, VIVS is projected to trade between $1.01 and $1.70, averaging $1.27 — a potential decline of -1% from today's $1.29. That is -1% versus the projected 2026 average. Price action looks broadly range-bound.
VivoSim Labs, Inc.'s 2028 outlook centres on $1.34, within a $1.03 to $1.84 range. That is up +5% on the projected 2027 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, VIVS could reach as high as $2.26, with a base case around $1.60 and support toward $1.21 — roughly +24% from $1.29. Momentum favours further upside here.
Expect VIVS to range from $1.18 to $2.31 through 2030. The $1.59 average target implies a +23% move from current prices. That is 0% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The VIVS price prediction for 2031 points to an average of $1.47 (low $1.08, high $2.18) — a potential gain of +14% on today's $1.29. Price action looks broadly range-bound.
In 2032, VIVS is projected to trade between $1.12 and $2.36, averaging $1.56 — a potential gain of +21% from today's $1.29. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
VivoSim Labs, Inc.'s 2033 outlook centres on $1.53, within a $1.08 to $2.34 range. That is -2% versus the projected 2032 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2034, VIVS could reach as high as $2.51, with a base case around $1.61 and support toward $1.12 — roughly +25% from $1.29. Buyers look set to stay in control over this stretch.
Expect VIVS to range from $1.32 to $3.04 through 2035. The $1.92 average target implies a +49% move from current prices. That is up +20% on the projected 2034 average. Momentum favours further upside here.
The VIVS price prediction for 2040 points to an average of $2.17 (low $1.40, high $3.64) — a potential gain of +68% on today's $1.29. Buyers look set to stay in control over this stretch.
In 2050, VIVS is projected to trade between $2.17 and $6.93, averaging $3.78 — a potential gain of +193% from today's $1.29. That is up +74% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VIVS today (≈ 775.193798 VIVS) could be worth
$2,929.77
+$1,929.77 (+193%) by 2050 · US Dollar
Based on the average projected VIVS price of $3.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VIVSwould be worth at today's price.
$1,000 invested in VIVS on May 27, 2025 (≈ 523.560219 VIVS) would be worth
$675.39
-$324.61 (-32.5%) today · 0.68× · US Dollar
Based on a VIVS entry price of $1.91 vs. today's $1.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.3 | $992.31 | -0.8% |
| 1 month ago | $1.5 | $860 | -14.0% |
| 3 months ago | $2.23 | $578.48 | -42.2% |
| 6 months ago | $2.24 | $575.89 | -42.4% |
| 1 year ago | $1.91 | $675.39 | -32.5% |
| All time (5.0y) ago | $103.08 | $12.51 | -98.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VIVS forecast.
Our base-case forecast reaches $2.60 around 2050.
Implied market cap at $2.60: $7.53M
The multi-year forecast depicts a trajectory from neutral in the near term toward bullish sentiment in the longer term, with rising average prices and sizable ROI potential. In 2029 the average price is $1.69 with an ROI of 24.2 and a bullish stance, followed by 2030 with an average of $1.67 and an ROI of 22.9 as bullish as well.
Further out, 2040 shows an average price of $2.29 with an ROI of 68.3 and a bullish sentiment, while 2050 projects an average of $3.99 with an ROI of 193.5, also labeled bullish. Other years show mixed timing, including neutral readings in some years (e.g., 2026-2028, 2031, 2033) with lower averages (e.g., 2027 avg $1.34; 2031 avg $1.55) and modest upside in 2035 (avg $2.04, ROI 50.1).
These figures are estimates and not guarantees, reflecting a path of potential appreciation with substantial upside in the far horizon and notable volatility across intermediate years.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $1.67 with a ROI of 22.9 and a bullish sentiment.
Forecasts indicate bullish sentiment in several late-years (e.g., 2029, 2030, 2040, 2050) with meaningful upside, but some years show neutral or negative ROI (e.g., 2027 ROI -1.3). These are estimates, not guarantees, and should be considered with caution.
The 2050 forecast shows an average of $3.99 with a maximum of $7.31, so reaching around $4 is within the implied upside range in the long term.
The current price is $1.36 and the market capitalization is $3.94M.
The RSI14 is 40, indicating neutral momentum. The price trades below the SMA50 of $1.51 and the SMA200 of $2.14, with support at $1.27 and resistance at $1.61; the 30-day range is $1.14 to $1.62, and annualized volatility is 50%.
VivoSim Labs, Inc. Community Discussion
0Share your VivoSim Labs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.